Patents Examined by Rebecca Anderson
  • Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors
    Patent number: 9617257
    Abstract: This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: April 11, 2017
    Assignee: Betta Pharmaceuticals Co., LTD
    Inventors: Shaojing Hu, Fei Wang, Zhiguo Xu, Yanping Wang, Yinxiang Wang
  • Phenylmorpholines and analogues thereof
    Patent number: 9617229
    Abstract: Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neurotransmitter levels, such as pre-obesity, obesity, addiction, and depression.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 11, 2017
    Assignees: Research Triangle Institute, The United States of America, As Represented by the Secretary Department of Health and Human Services
    Inventors: Bruce E. Blough, Richard Rothman, Antonio Landavazo, Kevin M. Page, Ann Marie Decker
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 9617248
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: April 11, 2017
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Lee William Page, Ildiko Maria Buck, James Edward Harvey Day, Steven Howard, Gordon Saxty, Christopher William Murray
  • Processes for preparing dihydropyrimidine derivatives and intermediates thereof
    Patent number: 9617252
    Abstract: The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (1a), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: April 11, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang Liu, Qingyun Ren, Zhifu Zou, Jinsheng Liang, Linjin Tu, Siegfried Goldmann, Yingjun Zhang
  • 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
    Patent number: 9611229
    Abstract: The present invention relates to new 1,2,3-triazole-amine derivatives, having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments for the treatment of sigma receptor related diseases and disorders.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 4, 2017
    Assignee: LABORATORIOS DEL DR. ESTEVE S.A.
    Inventors: Antoni Torrens-Jover, Ute Christmann, Josè-Luis Diaz-Fernández, Carmen Almansa-Rosales
  • Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers
    Patent number: 9611256
    Abstract: A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: April 4, 2017
    Assignees: The Hong Kong Polytechnic University, McGill University
    Inventors: Larry Ming Cheung Chow, Tak Hang Chan, Kin Fai Chan, Iris Lai King Wong, Man Chun Law
  • 5,5-heteroaromatic anti-infective compounds
    Patent number: 9605002
    Abstract: The invention provides a series of 5,5-heteroaromatic compounds, syntheses thereof, compositions thereof, and methods of using such compounds and compositions. Various embodiments provide methods of killing and/or inhibiting the growth of M. tuberculosis and/or M. avium, and methods of treating, preventing, and/or ameliorating M. tuberculosis and/or M. avium infections in a subject. In various embodiments, the 5,5-heteroaromatic compound is N-(4-(4-chlorophenoxy)benzyl)-2,6-dimethylimidazo[2,1-b]thiazole-5-carboxamide.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: March 28, 2017
    Assignee: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Garrett Moraski, Marvin J. Miller
  • Sulfide alkyl compounds for HBV treatment
    Patent number: 9597332
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: March 21, 2017
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: Austin Chen, Yalda Bravo, Nicholas Stock, Bijan Pedram, Jason Jacintho, Ryan C. Clark
  • Imidazopyridine compounds and uses thereof
    Patent number: 9598409
    Abstract: This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 21, 2017
    Assignee: Neomed Institute
    Inventors: Christophe Buon, Louis-David Cantin, Yun-Jin Hu, Xuehong Luo, Miroslaw Jerzy Tomaszewski
  • Cyclic amines
    Patent number: 9593105
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: March 14, 2017
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Nuclear transport modulators and uses thereof
    Patent number: 9585874
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: March 7, 2017
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Small molecule inhibitors of necroptosis
    Patent number: 9586880
    Abstract: Compounds having the following structure (VI-A): or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, wherein RE1, RE2, RE3, RE4, ZE2 and ZE3 are as disclosed herein, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating disorders associated with necrosptosis are also provided.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: March 7, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Junying Yuan, Emily P. Hsu
  • Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
    Patent number: 9580442
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 28, 2017
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Alexander R. Liam Cecil, Thomas J. Hill, Franck A. Silva
  • Saturated acyl guanidine for inhibition of FF-ATPase
    Patent number: 9580391
    Abstract: The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Modulators of pharmacokinetic properties of therapeutics
    Patent number: 9575080
    Abstract: The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: February 21, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Manoj C. Desai, Hongtao Liu, Lianhong Xu
  • Cathepsin cysteine protease inhibitors
    Patent number: 9573913
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: February 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn Stachel, Daniel V. Paone, Jing Li, Anthony Ginnetti, John Lim, Jianmin Fu, Shimin Xu
  • Compounds and compositions as kinase inhibitors
    Patent number: 9573969
    Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 21, 2017
    Assignee: NOVARTIS AG
    Inventors: Matthew T. Burger, Savithri Ramurthy, Benjamin R. Taft
  • Processes for preparing dihydropyrimidine derivatives and intermediates thereof
    Patent number: 9573941
    Abstract: The present invention relates to processes for preparing a dihydropyrimidine derivative having Formula (I) or a tautomer thereof having Formula (Ia), as well as a intermediate thereof. The processes of the invention have simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: February 21, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun Ren, Xinchang Liu, Zhifu Zou, Guanghua Yan, Mingchao Bi, Siegfried Goldmann, Yingjun Zhang
  • Pyrimidine compounds for the treatment of cancer
    Patent number: 9567326
    Abstract: Described are compounds of Formula I or Formula II: wherein: ring A is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 14, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Xiaodong Wang, Weihe Zhang, Dmitri Kireev, Dehui Zhang, Andrew McIver
  • Azabenzimidazole derivative having AMPK-activating activity
    Patent number: 9567330
    Abstract: Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, or substituted or unsubstituted alkyl, R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R1, R2 and R3 are not simultaneously hydrogen, X is a single bond, —S—, —O—, —NR5—, —C(?O)— or the like, R5 is hydrogen, or substituted or unsubstituted alkyl, Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 14, 2017
    Assignee: Shionogi & Co., Ltd.
    Inventors: Eiichi Kojima, Keisuke Tonogaki, Nobuyuki Tanaka, Manabu Katou, Akira Ino, Masafumi Iwatsu, Masahiko Fujioka, Yu Hinata, Naoki Ohyabu